StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
662
This month
5
This year
51
Publishing Date
2024 - 03 - 28
3
2024 - 03 - 18
3
2024 - 02 - 22
3
2024 - 02 - 12
4
2023 - 12 - 22
4
2023 - 12 - 12
3
2023 - 10 - 31
3
2023 - 10 - 17
3
2023 - 09 - 26
3
2023 - 09 - 22
4
2023 - 06 - 08
3
2023 - 05 - 30
3
2023 - 05 - 01
3
2023 - 04 - 05
3
2023 - 02 - 02
3
2023 - 01 - 27
3
2022 - 08 - 10
3
2022 - 06 - 06
3
2022 - 06 - 03
3
2022 - 06 - 02
3
2022 - 04 - 12
4
2022 - 04 - 05
3
2022 - 02 - 25
3
2021 - 11 - 12
3
2021 - 11 - 03
3
2021 - 10 - 01
3
2021 - 09 - 17
3
2021 - 09 - 16
3
2021 - 09 - 08
3
2021 - 08 - 19
3
2021 - 07 - 30
3
2021 - 07 - 09
3
2021 - 06 - 25
3
2021 - 06 - 17
3
2021 - 06 - 10
5
2021 - 06 - 04
3
2021 - 05 - 24
3
2021 - 05 - 20
5
2021 - 05 - 19
3
2021 - 05 - 18
4
2021 - 05 - 12
3
2021 - 05 - 05
2
2021 - 04 - 29
3
2021 - 04 - 28
4
2021 - 04 - 23
5
2021 - 04 - 22
2
2021 - 04 - 16
4
2021 - 04 - 14
3
2021 - 04 - 13
3
2021 - 04 - 12
2
2021 - 04 - 07
3
2021 - 03 - 25
2
2021 - 03 - 19
3
2021 - 03 - 11
2
2021 - 03 - 04
2
2021 - 01 - 20
2
2021 - 01 - 11
2
2021 - 01 - 04
2
2020 - 12 - 11
3
2020 - 12 - 08
2
Sector
Communications
4
Consumer non-durables
1
Distribution services
1
Electronic technology
2
Energy minerals
1
Finance
12
Health services
5
Health technology
662
Information
2
Manufacturing
38
N/a
12
Process industries
10
Producer manufacturing
3
Professional, scientific, and technical services
3
Retail trade
4
Technology services
6
Tags
Acquisition
8
Agreement
9
Alliances
21
Antibody
14
Application
22
Approval
48
Biotech-bay
15
Cancer
107
Cell
22
Cell carcinoma
11
Chmp
17
Clinical-trials-phase-ii
15
Clinical-trials-phase-iii
20
Collaboration
34
Conference
18
Disease
22
Drug
63
Earnings
24
Europe
16
Events
24
Expected
9
Fda
20
Financial
21
Financial results
17
Food
24
Genetown
11
Global
67
Growing
13
Growth
35
Health
9
Immunotherapy
17
Int230
9
Iot
11
License
12
Lung
16
Market
125
N/a
325
Nivolumab
60
Opdivo
33
People
13
Pharm-country
67
Pharmaceutical
13
Pharmaceuticals
9
Phase 1
10
Phase 2
15
Phase 3
12
Positive
27
Product-news
14
Reach
12
Renal
11
Report
67
Research
80
Results
64
Solid tumors
10
Study
9
Therapeutics
48
Therapy
65
Treatment
93
Trial
48
Update
10
Entities
2seventy bio, inc.
11
Abbott laboratories
26
Abbvie inc.
88
Adc therapeutics sa
13
Advaxis, inc.
8
Agenus inc.
5
Agios pharmaceuticals, inc.
12
Albemarle corporation
8
Alnylam pharmaceuticals, inc.
11
Amgen inc.
86
Astellas pharma inc
11
Astrazeneca plc
61
Aveo pharmaceuticals, inc.
19
Ayala pharmaceuticals, inc.
12
Bausch health companies inc.
10
Beigene, ltd.
12
Biocryst pharmaceuticals, inc.
13
Biogen inc.
11
Biomarin pharmaceutical inc.
5
Bluebird bio, inc.
8
Blueprint medicines corporation
19
Bolt biotherapeutics inc
7
Boston scientific corporation
6
Bristol-myers squibb company
662
Clovis oncology, inc.
20
Eli lilly and company
106
Epizyme, inc.
18
Evotec se
5
Evotec se - adr
5
Exelixis, inc.
29
Genmab a/s
6
Gilead sciences, inc.
45
Glaxosmithkline plc
67
Illumina, inc.
10
Incyte corporation
24
Intensity therapeutics, inc.
12
Johnson & johnson
91
Karuna therapeutics, inc.
6
Karyopharm therapeutics inc.
19
Medtronic plc
6
Mirati therapeutics, inc.
10
Nektar therapeutics
7
Novartis ag
103
Novo nordisk a/s
7
Omeros corporation
13
Otonomy, inc.
13
Pfizer, inc.
61
Regeneron pharmaceuticals, inc.
30
Replimune group, inc.
6
Rigel pharmaceuticals, inc.
11
Sanofi
119
Takeda pharmaceutical company limited
43
Teva pharmaceutical industries limited
8
Teva pharmaceutical industries ltd
37
Turning point therapeutics, inc.
7
Ucb s.a.
8
Verastem, inc.
11
Viatris inc.
15
Xeris pharmaceuticals, inc.
10
Y-mabs therapeutics, inc.
18
Symbols
ABBV
88
ABT
26
ADCT
13
ADXS
8
AGIO
12
ALB
8
ALNY
11
ALPMF
11
ALPMY
11
AMGN
86
AVEO
19
AYLA
12
AZN
61
AZNCF
53
BCRX
13
BGNE
12
BHC
10
BIIB
11
BLUE
8
BMY
662
BOLT
7
BPMC
19
BSX
6
CLVS
20
EPZM
18
EXEL
29
GILD
45
GLAXF
50
GMAB
6
GNMSF
6
GSK
67
ILMN
10
INCY
24
INTS
12
JNJ
91
KPTI
19
LLY
106
MRTX
10
NKTR
7
NVO
7
NVS
103
NVSEF
82
OMER
13
OTIC
13
PFE
61
REGN
30
RIGL
11
SNY
119
SNYNF
70
TAK
43
TEVA
8
TEVJF
37
TPTX
7
TSVT
11
UCBJF
8
UCBJY
8
VSTM
11
VTRS
15
XERS
10
YMAB
18
Exchanges
Amex
2
Nasdaq
390
Nyse
662
Crawled Date
2024 - 03 - 28
3
2024 - 03 - 18
3
2024 - 02 - 22
3
2024 - 02 - 12
4
2023 - 12 - 22
4
2023 - 12 - 12
3
2023 - 09 - 26
3
2023 - 09 - 22
4
2023 - 09 - 18
3
2023 - 06 - 08
3
2023 - 06 - 01
3
2023 - 05 - 30
3
2023 - 05 - 01
3
2023 - 04 - 05
3
2023 - 02 - 02
3
2023 - 01 - 27
3
2022 - 08 - 10
3
2022 - 06 - 06
3
2022 - 06 - 03
3
2022 - 06 - 02
3
2022 - 04 - 12
4
2022 - 04 - 05
3
2022 - 02 - 25
3
2021 - 11 - 12
3
2021 - 11 - 03
3
2021 - 10 - 01
3
2021 - 09 - 17
3
2021 - 09 - 16
3
2021 - 09 - 08
3
2021 - 08 - 19
3
2021 - 07 - 30
3
2021 - 07 - 27
3
2021 - 07 - 09
3
2021 - 06 - 25
3
2021 - 06 - 10
5
2021 - 06 - 04
3
2021 - 05 - 25
4
2021 - 05 - 20
5
2021 - 05 - 19
3
2021 - 05 - 18
4
2021 - 05 - 12
3
2021 - 04 - 29
3
2021 - 04 - 28
4
2021 - 04 - 23
5
2021 - 04 - 22
2
2021 - 04 - 16
4
2021 - 04 - 15
2
2021 - 04 - 14
2
2021 - 04 - 13
4
2021 - 04 - 07
3
2021 - 03 - 29
2
2021 - 03 - 25
2
2021 - 03 - 19
3
2021 - 03 - 11
2
2021 - 03 - 04
2
2021 - 01 - 20
2
2021 - 01 - 11
2
2021 - 01 - 04
2
2020 - 12 - 11
3
2020 - 12 - 08
2
Crawled Time
00:00
18
00:01
1
01:00
10
02:00
6
03:00
3
04:00
2
04:20
3
05:00
1
06:00
3
07:00
4
08:00
11
08:20
1
09:00
5
10:00
8
10:41
1
10:43
1
10:51
2
10:57
1
11:00
22
11:36
1
12:00
108
12:01
1
12:02
1
12:04
1
12:15
15
12:20
17
12:24
1
12:30
10
12:34
1
13:00
67
13:07
1
13:13
1
13:15
4
13:17
1
13:20
10
13:27
1
13:30
8
13:50
1
14:00
38
14:03
1
14:15
1
14:20
7
14:30
7
14:58
1
15:00
29
15:15
2
15:20
4
15:30
6
16:00
31
16:20
3
17:00
24
18:00
22
18:04
2
18:26
2
18:31
2
19:00
16
20:00
25
21:00
27
22:00
22
23:00
18
Source
feed.businesswire.com
2
mindmed.co
1
savarapharma.com
1
www.biospace.com
336
www.fda.gov
46
www.globenewswire.com
47
www.prnewswire.com
229
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Bristol-myers squibb company
symbols :
Bmy
save search
Pomerantz Law Firm Announces the Filing of a Class Action Against VinFast Auto Ltd. and Certain Officers - VFS
Published:
2024-04-12
(Crawled : 20:00)
- prnewswire.com
FICO
|
$1153.28
0.05%
0.0%
180K
|
Technology Services
|
Email alert
Add to watchlist
VFS
|
News
|
$2.72
-11.4%
-12.87%
6.3M
|
|
Email alert
Add to watchlist
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
Email alert
Add to watchlist
BSAQ
|
News
|
$10.2
2.45%
380
|
|
Email alert
Add to watchlist
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published:
2024-04-08
(Crawled : 18:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-0.62%
|
O:
2.24%
H:
0.0%
C:
-0.8%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
1.57%
|
O:
-3.43%
H:
6.21%
C:
6.21%
VTRS
|
$11.095
-0.22%
-0.23%
6.1M
|
Health Technology
|
-5.76%
|
O:
-0.25%
H:
1.1%
C:
-0.17%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-3.1%
|
O:
-0.05%
H:
0.43%
C:
-0.27%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-5.96%
|
O:
-0.08%
H:
0.04%
C:
-0.35%
BHC
|
$8.66
-0.92%
0.0%
2.2M
|
Health Technology
|
-16.04%
|
O:
0.38%
H:
0.0%
C:
-7.27%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
-3.2%
|
O:
0.77%
H:
1.63%
C:
0.35%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.25%
|
O:
0.84%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
1.21%
|
O:
0.18%
H:
0.3%
C:
0.19%
eczema
dermatitis
set
therapeutics
market
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published:
2024-04-05
(Crawled : 14:00)
- biospace.com/
TSVT
|
$5.06
4.12%
3.95%
900K
|
|
-2.99%
|
O:
7.98%
H:
9.06%
C:
-9.06%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-6.11%
|
O:
-0.41%
H:
0.51%
C:
0.25%
fda
for
therapy
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published:
2024-04-03
(Crawled : 08:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-8.49%
|
O:
-0.08%
H:
0.3%
C:
-0.99%
reblozyl
anemia
approval
treatment
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Published:
2024-04-02
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-8.93%
|
O:
0.21%
H:
0.47%
C:
-0.68%
report
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published:
2024-03-29
(Crawled : 18:00)
- prnewswire.com
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
Email alert
Add to watchlist
GILD
|
$66.94
-0.55%
-0.55%
5.3M
|
Health Technology
|
Email alert
Add to watchlist
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
Email alert
Add to watchlist
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
Email alert
Add to watchlist
GMAB
|
$28.51
-3.13%
-3.23%
360K
|
Health Technology
|
Email alert
Add to watchlist
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
Email alert
Add to watchlist
GNMSF
|
$285.11
3.83%
420
|
Health Technology
|
Email alert
Add to watchlist
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
Email alert
Add to watchlist
research
global
leukemia
therapeutics
market
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published:
2024-03-28
(Crawled : 22:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-9.37%
|
O:
0.26%
H:
2.03%
C:
1.57%
first
disease
active
update
trial
Global Antibody Therapeutic Industry Research 2023-2024 & 2033: Exploring the Expanding Role in Managing Cancer, Autoimmune Disorders, and Infectious Diseases
Published:
2024-03-28
(Crawled : 15:30)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-4.72%
|
O:
0.99%
H:
0.0%
C:
0.0%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
-2.13%
|
O:
-100.0%
H:
NaN%
C:
Infinity%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-3.19%
|
O:
0.52%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.46%
|
O:
1.32%
H:
0.0%
C:
0.0%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-7.07%
|
O:
0.02%
H:
0.51%
C:
-0.3%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
-4.04%
|
O:
0.28%
H:
1.71%
C:
-0.3%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-9.37%
|
O:
0.26%
H:
2.03%
C:
1.57%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-6.88%
|
O:
0.54%
H:
0.0%
C:
0.0%
antibody
research
global
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
Published:
2024-03-28
(Crawled : 12:00)
- globenewswire.com
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-9.37%
|
O:
0.26%
H:
2.03%
C:
1.57%
LNTH
|
$61.49
-0.39%
-0.39%
540K
|
Health Technology
|
2.1%
|
O:
-0.25%
H:
3.58%
C:
3.2%
business
year
therapeutics
financial
results
Pharmaceutical Market In Canada size is set to grow by USD 8.73 bn from 2024-2028, Abbott Laboratories, AbbVie Inc. & Amgen Inc., and more to emerge as Some of the Key Vendors, Technavio
Published:
2024-03-27
(Crawled : 22:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-4.72%
|
O:
0.99%
H:
0.0%
C:
0.0%
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-7.61%
|
O:
-1.17%
H:
0.0%
C:
-0.89%
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
0.45%
|
O:
0.89%
H:
0.78%
C:
0.78%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
-2.13%
|
O:
-100.0%
H:
NaN%
C:
Infinity%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-3.19%
|
O:
0.52%
H:
0.0%
C:
0.0%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-7.07%
|
O:
0.02%
H:
0.51%
C:
-0.3%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-9.37%
|
O:
0.26%
H:
2.03%
C:
1.57%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
-9.88%
|
O:
0.36%
H:
0.72%
C:
0.61%
ABT
|
News
|
$105.9
-3.03%
0.07%
12M
|
Health Technology
|
-2.55%
|
O:
1.04%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-7.74%
|
O:
-0.96%
H:
0.0%
C:
0.0%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
0.01%
|
O:
-0.12%
H:
0.25%
C:
-0.63%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-6.88%
|
O:
0.54%
H:
0.0%
C:
0.0%
abbvie
set
canada
key
market
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Published:
2024-03-26
(Crawled : 13:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-7.64%
|
O:
0.27%
H:
0.5%
C:
0.31%
health
grant
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
Published:
2024-03-25
(Crawled : 13:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-7.07%
|
O:
0.29%
H:
1.27%
C:
0.33%
cardiovascular
cardiology
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published:
2024-03-20
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-6.83%
|
O:
-0.33%
H:
1.02%
C:
0.48%
opdivo
treatment
trial
advanced
plus
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Published:
2024-03-18
(Crawled : 15:30)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-7.8%
|
O:
0.46%
H:
0.23%
C:
-1.88%
acquisition
therapeutics
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Published:
2024-03-18
(Crawled : 13:30)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-7.8%
|
O:
0.46%
H:
0.23%
C:
-1.88%
acquisition
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
Published:
2024-03-18
(Crawled : 12:00)
- globenewswire.com
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-7.8%
|
O:
0.46%
H:
0.23%
C:
-1.88%
vmt01
melanoma
nivolumab
collaboration
therapeutics
agreement
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published:
2024-03-15
(Crawled : 23:00)
- biospace.com/
TSVT
|
$5.06
4.12%
3.95%
900K
|
|
22.73%
|
O:
2.27%
H:
8.4%
C:
-0.99%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-8.06%
|
O:
-0.32%
H:
1.67%
C:
0.04%
fda
therapy
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
Published:
2024-03-11
(Crawled : 23:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-10.28%
|
O:
0.2%
H:
1.22%
C:
0.85%
first
report
results
FDA Roundup: March 8, 2024
Published:
2024-03-08
(Crawled : 20:00)
- prnewswire.com
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
Email alert
Add to watchlist
fda
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Published:
2024-03-07
(Crawled : 12:00)
- prnewswire.com
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-5.52%
|
O:
0.04%
H:
0.44%
C:
-1.51%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
-9.57%
|
O:
-2.08%
H:
0.13%
C:
-0.57%
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-9.59%
|
O:
0.36%
H:
0.34%
C:
-0.54%
XFOR
|
$1.19
-9.85%
-10.92%
2.5M
|
Health Technology
|
37.0%
|
O:
0.12%
H:
0.0%
C:
-4.98%
EYPT
|
$20.94
-4.12%
-4.3%
510K
|
Health Technology
|
-15.15%
|
O:
2.56%
H:
1.37%
C:
-4.13%
AQST
|
$3.915
1.69%
1.66%
2.4M
|
Health Technology
|
-23.46%
|
O:
1.79%
H:
12.3%
C:
10.94%
ALKS
|
News
|
$24.05
1.18%
1.16%
2.3M
|
Health Technology
|
-17.86%
|
O:
1.11%
H:
0.96%
C:
0.65%
← Previous
1
2
3
4
5
6
7
8
9
…
33
34
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.